Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
2019 ◽
Vol 22
(4)
◽
pp. 344-349
◽
2016 ◽
Vol 34
(15_suppl)
◽
pp. e20636-e20636
2017 ◽
Vol Volume 9
◽
pp. 505-518
◽